RTW Venture Fund Limited Monthly Valuation Update & Factsheet (1612Z)
12 Mayo 2023 - 1:00AM
UK Regulatory
TIDMRTW
RNS Number : 1612Z
RTW Venture Fund Limited
12 May 2023
LEI: 549300Q7EXQQH6KF7Z84
12 May 2023
RTW Venture Fund Limited
Monthly Valuation Update & Factsheet
+13% NAV movement
RTW Venture Fund Limited (the "Company") announces that the
unaudited net asset value attributable to the ordinary shares of
the Company at the close of business on 30 April 2023 (the "NAV")
was US$358.6 million, or US$1.69 per ordinary share, an increase of
13% from the previous month.
The monthly factsheet is available on the Company's website:
https://www.rtwfunds.com/rtw-venture-fund-ltd/factsheets-letters/
For Further Information:
RTW Investments, LP +44 (0)20 7959 6361
Woody Stileman, Managing Director
Krisha McCune, Director, Client Service
Buchanan +44 (0)20 7466 5107
Charles Ryland
Henry Wilson
George Beale
Numis +44 (0)20 7260 1000
Freddie Barnfield
Nathan Brown
Euan Brown
BofA Securities +44 (0) 20 7628 1000
Edward Peel
Kieran Millar
Elysium Fund Management Limited +44 (0) 14 8181 0100
Joanna Duquemin Nicolle, Chief Executive Officer
Sadie Morrison, Managing Director
Morgan Stanley Fund Services USA LLC +1 (914) 225 8885
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment
fund focused on identifying transformative assets with high growth
potential across the biopharmaceutical and medical technology
sectors. Driven by a long-term approach to support innovative
businesses, RTW Venture Fund invests in companies developing
next-generation therapies and technologies that can significantly
improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a
leading healthcare-focused entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more
information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DOCBLGDUGGBDGXB
(END) Dow Jones Newswires
May 12, 2023 02:00 ET (06:00 GMT)
Rtw Biotech Opportunities (LSE:RTWG)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Rtw Biotech Opportunities (LSE:RTWG)
Gráfica de Acción Histórica
De May 2023 a May 2024